Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTXNASDAQ:CGIXNASDAQ:ENVBNASDAQ:ISPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.41-3.7%$2.07$1.34▼$27,200.00$2.99M1.49792,987 shs12,527 shsCGIXCancer Genetics$0.19$0.26$2.11▼$17.50$792K2.722.44 million shs19,116 shsENVBEnveric Biosciences$1.23+0.0%$1.26$1.01▼$11.82$3.04M0.53766,332 shs7,765 shsISPCiSpecimen$1.22-1.8%$1.21$1.02▼$11.80$3.04M1.69381,973 shs1,800 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-1.68%-6.09%-18.16%-82.46%-99.99%CGIXCancer Genetics0.00%0.00%0.00%0.00%0.00%ENVBEnveric Biosciences-3.91%-4.65%-9.23%-25.00%-88.92%ISPCiSpecimen-1.59%-0.80%+5.98%-2.36%+226.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxt1.0698 of 5 stars0.05.00.00.02.50.00.6CGIXCancer GeneticsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences2.2189 of 5 stars3.52.00.00.02.40.01.3ISPCiSpecimen0.6015 of 5 stars0.03.00.00.01.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/ACGIXCancer Genetics 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00712.94% UpsideISPCiSpecimen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$55.32K54.04N/AN/A$2,687.49 per share0.00CGIXCancer Genetics$6.33M0.13N/AN/AN/A∞ENVBEnveric BiosciencesN/AN/AN/AN/A$10.71 per shareN/AISPCiSpecimen$8.06M0.38N/AN/A$21.47 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$32.38MN/A0.00∞N/AN/A-439.07%-122.96%8/18/2025 (Estimated)CGIXCancer GeneticsN/A-$2.07N/A∞N/AN/AN/AN/AN/AENVBEnveric Biosciences-$17.29M-$38.38N/AN/AN/AN/A-221.54%-164.32%8/11/2025 (Estimated)ISPCiSpecimen-$11.10M-$12.89N/A∞N/A-91.66%-139.25%-73.97%N/ALatest CGIX, ENVB, ADTX, and ISPC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025ISPCiSpecimenN/A-$0.71N/A-$0.71N/A$1.06 million5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/A4/14/2025Q4 2024ISPCiSpecimen-$4.00-$6.28-$2.28-$6.28$2.98 million$1.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/ACGIXCancer GeneticsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AISPCiSpecimenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.090.08CGIXCancer GeneticsN/AN/AN/AENVBEnveric BiosciencesN/A5.175.17ISPCiSpecimenN/A0.740.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%CGIXCancer Genetics8.92%ENVBEnveric Biosciences13.82%ISPCiSpecimen13.62%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%CGIXCancer Genetics15.00%ENVBEnveric Biosciences1.10%ISPCiSpecimen12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt602.12 million14.23 millionNo DataCGIXCancer GeneticsN/A4.09 millionN/ANot OptionableENVBEnveric Biosciences202.47 million656,000Not OptionableISPCiSpecimen602.50 million846,000Not OptionableCGIX, ENVB, ADTX, and ISPC HeadlinesRecent News About These CompaniesiSpecimen Inc. (ISPC) Stock Price, News, Quote & History - Yahoo FinanceFebruary 22, 2025 | finance.yahoo.comiSpecimen Stock Hits 52-Week Low at $1.81 Amid Market ChallengesFebruary 12, 2025 | msn.comiSpecimen stock hits 52-week low at $1.96 amid market challengesFebruary 3, 2025 | msn.comThe iSpecimen Inc Rollercoaster: What’s Behind the Latest ISPC Stock Fluctuation?January 21, 2025 | bovnews.comiSpecimen (NASDAQ: ISPC) Secures Suppliers for Human Metapneumovirus (hMPV) Specimens Amid Growing ConcernsJanuary 17, 2025 | kalkinemedia.comiSpecimen (ISPC) Makes Strategic Moves as Virus Concerns Ignite Stock SurgeJanuary 17, 2025 | bovnews.comiSpecimen Shares Rise After Securring Virus SuppliersJanuary 16, 2025 | marketwatch.comiSpecimen Secures Suppliers for COVID-style hMPV OutbreakJanuary 16, 2025 | newsfilecorp.comiSpecimen Strengthens Leadership and Expands Cancer Research FocusDecember 20, 2024 | tipranks.comiSpecimen Will Serve as a Preferred Provider of Cancer BiospecimensDecember 20, 2024 | newsfilecorp.comiSpecimen Inc (ISPC) Stock’s -0.73% Decrease This Year: What’s the Story?December 14, 2024 | bovnews.comiSpecimen Reports Positive Results on Next Day Quote Program for Researchers and ProvidersDecember 13, 2024 | newsfilecorp.comiSpecimen Appoints Robert Lim as New CEODecember 12, 2024 | markets.businessinsider.comiSpecimen Appoints Robert Lim as CEO and DirectorDecember 12, 2024 | newsfilecorp.comiSpecimen Inc. Reports Earnings Amid Financial ChallengesNovember 9, 2024 | markets.businessinsider.comiSpecimen Reports Third Quarter 2024 ResultsNovember 8, 2024 | markets.businessinsider.comiSpecimen releases cancer biospecimen offeringNovember 8, 2024 | markets.businessinsider.comISPC Unveiled: The Shocking Truth Behind iSpecimen Inc’s Latest Stock MovementsNovember 8, 2024 | bovnews.comiSpecimen Named Top Competitor in $4.4 Billion USD MarketNovember 8, 2024 | newsfilecorp.comiSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 AnnuallyNovember 7, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGIX, ENVB, ADTX, and ISPC Company DescriptionsAditxt NASDAQ:ADTX$1.41 -0.05 (-3.73%) As of 10:09 AM EasternAditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Cancer Genetics NASDAQ:CGIXVyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.Enveric Biosciences NASDAQ:ENVB$1.23 +0.00 (+0.01%) As of 09:48 AM EasternEnveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.iSpecimen NASDAQ:ISPC$1.22 -0.02 (-1.78%) As of 10:00 AM EasterniSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alibaba’s Dip Is a Gift—Here’s the Price That Matters GameStop Turns a Profit, But Core Business Keeps Shrinking Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
